The distressed biotech firm, NovaGen Therapeutics, faced significant fiscal difficulties stemming from failed clinical trials and mounting debt. Their internal team lacked the experience to navigate the https://emilielkzu560477.mpeblog.com/74302972/biotech-cfo-services-a-case-study-in-monetary-restructuring